Abstract: SA-PO0032
AKI After Repeated COVID-19 Disease (C19D) and Vaccination (C19V)
Session Information
- AKI: Novel Patient Populations and Case Reports
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 101 AKI: Epidemiology, Risk Factors, and Prevention
Authors
- Teixeira, J. Pedro, University of New Mexico, Department of Internal Medicine, Albuquerque, New Mexico, United States
- Roumelioti, Maria-Eleni, University of New Mexico, Department of Internal Medicine, Albuquerque, New Mexico, United States
- Garcia, Pablo, University of New Mexico, Department of Internal Medicine, Albuquerque, New Mexico, United States
- Mir, Hamza, University of New Mexico, Department of Internal Medicine, Albuquerque, New Mexico, United States
- Argyropoulos, Christos, University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States
Background
C19D contributes to Acute Kidney Injury (AKI), while concerns have been voiced recently about the safety of C19V. We analyzed the population risk of AKI associated with repeat C19V & C19D.
Methods
We included all patients who had a C19 test between 3/1/20-3/31/24 in any US institute in the TrinetX database and a baseline serum creatinine (SCr) before 3/1/20. SCr, C19V, and C19D were assessed. AKI was defined by changes of consecutive SCr values & staged according to KDIGO criteria. Resolution of AKI was defined as SCr returning to baseline within 3 months. If AKI didn't resolve, a new baseline was defined and used to stage repeat AKI episodes. Penalized, logistic regression was used to quantify the odds of AKI adjusting for demographics and setting of SCr testing.
Results
We included 3,244,124 pts and 32,706,960 SCr measurements. Age was 55.4 ±17 y/o, baseline eGFR 91.2 ± 23.0, 59% of pts were female; number of C19D, C19V , C19T and AKI episodes per participant were 0.54 ± 1.12, 0.3 ± 0.7, 1.7 ± 1.6 , 0.43 ± 1.2 respectively. There were 1,380,135 episodes of AKI, staged as 1 (91.3%), 2 (7.4%) and 3 (1.4%). Uninfected pts had the lowest risk of AKI, while the C19V was not associated with AKI (table). Risk of severe (stage 2/3) AKI varied over time among participants with AKI (Figure).
Conclusion
C19D, but not C19V is associated with AKI. The RR of C19D is understimated in our analyses since many infections were diagnosed with home tests and thus not captured in TriNetX.
Adjusted Odds Ratio and 95% CI for AKI
| Uninfected | 0.86 (0.82-0.89) |
| 1st C19D | 0.99 (0.96-1.03) |
| 2nd C19D | 0.97 (0.93-1.01) |
| 3rd C19D | 1.04 (1.00-1.09) |
| 4th C19D | 1.08 (1.01-1.15) |
| 5th C19D | 1.04 (0.98-1.10) |
| Unvaccinated | 0.99 (0.97-1.01) |
| 1st C19V | 0.99 (0.98-1.01) |
| 2nd C19V | 1.02 (1.00-1.03) |
| 3rd C19V | 1.00 (0.99-1.01) |
| 4th C19V | 1.01 (0.99-1.02) |
| 5th C19V | 1.00 (0.98-1.01) |
Funding
- Other NIH Support